GlassScriptPhysician profile
Raakesh C Bhan
NPI 1649278516
$5,560.01
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $451 · 2021: $490 · 2022: $909 · 2023: $1,393 · 2024: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $432.13 | 2019-2024 | Farxiga |
| Welch Allyn | $383.73 | 2021 | |
| Lilly USA, LLC | $370.34 | 2020-2024 | Mounjaro, Trulicity, Jardiance |
| Novartis Pharmaceuticals Corporation | $368.65 | 2019-2024 | |
| Amgen INC. | $337.30 | 2019-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $329.37 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $319.12 | 2019-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $275.69 | 2022-2024 | Verquvo, Belsomra |
| Abbvie INC. | $225.99 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Mylan Specialty L.P. | $211.95 | 2019-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $182.28 | 2022-2024 | Austedo Xr, Austedo, Ajovy |
| Janssen Pharmaceuticals, INC | $181.26 | 2019-2022 | |
| Baxter Healthcare | $153.49 | 2022 | |
| Pfizer INC. | $152.07 | 2019-2024 | |
| Neurelis, INC. | $146.97 | 2023-2024 | Valtoco |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raakesh Bhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.